Research and Markets: Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/rsgskj/lyrica) has announced the addition of the "Lyrica (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.

Lyrica (pregabalin) is a compound with both analgesic and anticonvulsant properties that was developed by Pfizer as a follow-up brand to gabapentin (Neurontin). Pregabalin is the active pharmaceutical ingredient in Lyrica, and it binds with high affinity to the a-2-d site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues, and functions mechanistically to reduce pain.

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Lyrica including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top seven countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

  • Painful Diabetic Neuropathy
  • Postherpetic Neuralgia
  • Trigeminal Neuralgia
  • Etiology and Pathophysiology

4 Disease Management

  • Diagnosis
  • Treatment Overview and Guidelines

5 Competitive Assessment

6 Lyrica

  • Efficacy
  • Painful Diabetic Neuropathy
  • Postherpetic Neuralgia
  • Safety
  • SWOT Analysis
  • Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/rsgskj/lyrica

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System